Kaye Scholer Advises Pfizer in Exclusive Worldwide Licensing Agreement with Gliknik

Kaye Scholer client Pfizer Inc. has entered into an exclusive worldwide licensing agreement with Gliknik Inc., a privately held biopharmaceutical company, for GL-2045, Gliknik’s recombinant stradomer™, a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin.

Under the terms of the agreement, Pfizer will receive an exclusive worldwide license to GL-2045 for all therapeutic indications. Gliknik will receive an upfront payment of $25 million and is eligible to receive development, regulatory and commercial milestone payments. Gliknik is also eligible to receive tiered, double-digit royalties on net sales of any products that are commercialized pursuant to the licensing agreement.

The Kaye Scholer team that advised Pfizer included Partners Adam Golden and Andres Liivak and Associates Konstantinos Yiannopoulos,  Viktoriya Karshenboyem and Tracy Romano.